Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Chimerix Inc (CMRX)

Chimerix Inc (CMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 268,909
  • Shares Outstanding, K 89,936
  • Annual Sales, $ 320 K
  • Annual Income, $ -82,100 K
  • EBIT $ -93 M
  • EBITDA $ -100 M
  • 60-Month Beta 1.02
  • Price/Sales 829.96
  • Price/Cash Flow N/A
  • Price/Book 1.97

Options Overview Details

View History
  • Implied Volatility 117.04% ( -17.86%)
  • Historical Volatility 334.74%
  • IV Percentile 80%
  • IV Rank 19.57%
  • IV High 532.16% on 11/15/24
  • IV Low 16.00% on 03/06/24
  • Put/Call Vol Ratio 0.21
  • Today's Volume 277
  • Volume Avg (30-Day) 2,209
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 11,613
  • Open Int (30-Day) 14,816

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.26
  • Number of Estimates 4
  • High Estimate -0.22
  • Low Estimate -0.31
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.81 +276.50%
on 12/02/24
3.39 -10.03%
on 12/10/24
+2.15 (+238.89%)
since 11/22/24
3-Month
0.80 +281.25%
on 10/15/24
3.39 -10.03%
on 12/10/24
+2.20 (+257.35%)
since 09/23/24
52-Week
0.75 +306.67%
on 08/13/24
3.39 -10.03%
on 12/10/24
+2.12 (+227.53%)
since 12/22/23

Most Recent Stories

More News
Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Drug

Following the news, JonesResearch raised its price target on Chimerix to $7 from $5 while maintaining a ‘Buy’ rating.

CMRX : 2.98 (-0.33%)
Chimerix Plans NDA Submission for Dordaviprone in H3 K27M-Mutant Diffuse Glioma, Targeting Q3 2025 Approval

Chimerix plans to submit an NDA for dordaviprone to treat recurrent H3 K27M-mutant glioma by year-end 2024.Quiver AI SummaryChimerix, a biopharmaceutical company, announced plans to submit a New Drug Application...

CMRX : 2.98 (-0.33%)
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

CMRX : 2.98 (-0.33%)
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CMRX : 2.98 (-0.33%)
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement.

SIGA : 5.95 (+0.68%)
EBS : 8.06 (-0.49%)
GOVX : 2.14 (-6.55%)
CMRX : 2.98 (-0.33%)
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting

CMRX : 2.98 (-0.33%)
Chimerix: Q3 Earnings Snapshot

Chimerix: Q3 Earnings Snapshot

CMRX : 2.98 (-0.33%)
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

CMRX : 2.98 (-0.33%)
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

CMRX : 2.98 (-0.33%)
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CMRX : 2.98 (-0.33%)

Business Summary

Chimerix is a biopharmaceutical company which develop medicines for lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program ONC201, is in development for H3 K27M-mutant glioma. Chimerix is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 3.59
2nd Resistance Point 3.40
1st Resistance Point 3.19
Last Price 2.98
1st Support Level 2.79
2nd Support Level 2.60
3rd Support Level 2.39

See More

52-Week High 3.39
Last Price 2.98
Fibonacci 61.8% 2.38
Fibonacci 50% 2.07
Fibonacci 38.2% 1.76
52-Week Low 0.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar